<DOC>
	<DOC>NCT01063556</DOC>
	<brief_summary>The purpose of this study is to investigate the pharmacokinetics of donepezil HCl 3 mg in subjects with end-state renal disease who were receiving haemodialysis.</brief_summary>
	<brief_title>Pharmacokinetics Study of Donepezil HCl in Subjects Receiving Haemodialysis.</brief_title>
	<detailed_description>This is a randomised, single-center, open-label, single-dose, two-period crossover pharmacokinetics study of donepezil HCl tablets 3 mg in subjects receiving haemodialysis. Subjects will be or will not be receiving haemodialysis. After intervals of over 15 days, the subjects will be receiving the other treatment.</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Inclusion criteria: Subjects with endstage renal disease who were receiving haemodialysis. Subject who are able and willing to give written informed consent. Exclusion criteria: Subjects with known hypersensitivity to drugs or foods. Subjects with a corrected QT interval greater than 450 msec at Screening period.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>end-stage renal disease hemodialysis donepezil hydrochloride pharmacokinetics Cross-Over Study</keyword>
</DOC>